Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;31(1):101-111.
doi: 10.1016/j.hoc.2016.08.012.

Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Kathryn C Arbour  1 , Gregory J Riely  2
Affiliations
Review

Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Kathryn C Arbour et al. Hematol Oncol Clin North Am. 2017 Feb.

Abstract

Anaplastic lymphoma kinase (ALK) gene rearrangements occur in a small portion of patients with non-small cell lung cancer (NSCLC). These gene rearrangements lead to constitutive activation of the ALK kinase and subsequent ALK-driven tumor formation. Patients with tumors harboring such rearrangements are highly sensitive to ALK inhibitors, such as crizotinib, ceritinib, and alectinib. Resistance to these kinase inhibitors occurs through several mechanisms, resulting in ongoing clinical challenges. This review summarizes the biology of ALK-positive lung cancer, methods for diagnosing ALK-positive NSCLC, current FDA-approved ALK inhibitors, mechanisms of resistance to ALK inhibition, and potential strategies to combat resistance.

Keywords: Alectinib; Anaplastic lymphoma kinase inhibitors (ALK inhibitors); Ceritinb; Crizotinib; EML4-ALK rearrangement; Non–small cell lung cancer (NSCLC).

PubMed Disclaimer

References

    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi: 10.1038/nature05945. - DOI - PubMed
    1. Rikova K, Guo A, Zeng Q, et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer. Cell. 2007;131(6):1190–1203. doi: 10.1016/j.cell.2007.11.025. - DOI - PubMed
    1. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population. Clin Cancer Res. 2009;15(16):5216–5223. doi: 10.1158/1078-0432.CCR-09-0802. - DOI - PMC - PubMed
    1. Wong DWS, Leung ELH, So KKT, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723–1733. doi: 10.1002/cncr.24181. - DOI - PubMed
    1. Paik PK, Johnson ML, D'Angelo SP, et al. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer. 2012;118(23):5840–5847. doi: 10.1002/cncr.27637. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources